Coya Therapeutics, Inc. COYA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,793.53% | 115.43% | 123.57% | -58.26% | -95.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,793.53% | 115.43% | 123.57% | -58.26% | -95.57% |
| Cost of Revenue | 30.27% | 12.02% | 41.03% | 19.01% | 19.55% |
| Gross Profit | 28.93% | 25.14% | -5.74% | -391.24% | -833.21% |
| SG&A Expenses | 18.89% | 36.66% | 28.85% | 13.07% | 12.50% |
| Depreciation & Amortization | -29.41% | -14.71% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.27% | 21.74% | 35.77% | 16.36% | 16.37% |
| Operating Income | 7.83% | -3.99% | -17.65% | -80.39% | -120.70% |
| Income Before Tax | -2.88% | -18.30% | -36.04% | -92.01% | -124.61% |
| Income Tax Expenses | 100.43% | 100.43% | 100.43% | -199.50% | -199.50% |
| Earnings from Continuing Operations | -6.54% | -23.29% | -42.64% | -72.29% | -101.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.54% | -23.29% | -42.64% | -72.29% | -101.38% |
| EBIT | 7.83% | -3.99% | -17.65% | -80.39% | -120.70% |
| EBITDA | 7.81% | -4.01% | -17.68% | -80.59% | -121.03% |
| EPS Basic | 14.08% | -7.15% | -28.71% | -59.66% | -61.00% |
| Normalized Basic EPS | 27.69% | 9.35% | -10.12% | -84.11% | -87.23% |
| EPS Diluted | 14.08% | -7.15% | -28.71% | -59.66% | -61.00% |
| Normalized Diluted EPS | 27.69% | 9.35% | -10.12% | -84.11% | -87.23% |
| Average Basic Shares Outstanding | 22.38% | 15.23% | 9.79% | 19.61% | 29.13% |
| Average Diluted Shares Outstanding | 22.38% | 15.23% | 9.79% | 19.61% | 29.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |